Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

CIT is dead, says Radient in their SEC filings, and I think they have the final word.

I suggest you read the final 10-K:

https://www.sec.gov/Archives/edgar/data/838879/000114420412037312/v316641_10k.htm

Due to the following conditions at December 31, 2010, we decided to impair the remaining balance of our CIT asset:


· Lack of any potential future revenue;
· Lack of future cash flows;
· High cost of future clinical studies; and
· Limited time remaining on the patent.

Regarding GCDx: Your information is outdated, from mid 2012. That license agreement was never paid for and was therefore terminated. I suggest you read this SEC filing:

https://www.sec.gov/Archives/edgar/data/838879/000114420412054967/v325211_8ka.htm

"As of October 1, 2012, GCDx has not made the required upfront payment of $280,000. Therefore the proposed GCDx licensing agreement was cancelled."